NCT04261517View on ClinicalTrials.gov

Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 6, 2020

Primary Completion Date

February 25, 2020

Study Completion Date

February 25, 2020

Conditions
Pneumonia, PneumocystisCoronavirusCOVID-19
Interventions
DRUG

Hydroxychloroquine

Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments

Trial Locations (2)

201508

Shanghai Public Health Clinical Center, Shanghai

Unknown

Shanghai Public Health Clinical Center, Shanghai

All Listed Sponsors
lead

Shanghai Public Health Clinical Center

OTHER_GOV

NCT04261517 - Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19 | Biotech Hunter | Biotech Hunter